Spago Nanomedical AB Market Cap ($2.39 Million)
Market Cap & Net Worth: Spago Nanomedical AB (SPAGO)
Spago Nanomedical AB market cap. Spago Nanomedical AB (ST:SPAGO) has a market capitalization of $2.39 Million (Skr22.23 Million) as of November 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #29813 globally and #673 in its home market, demonstrating a -28.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Spago Nanomedical AB's stock price Skr0.03 by its total outstanding shares 661572786 (661.57 Million). Also see SPAGO cash generation efficiency for how efficiently the company converts equity into cash flow.
Spago Nanomedical AB Market Cap History (2015–2026)
Spago Nanomedical AB market cap history from 2015 to 2026. Data shows change from $1.02 Billion to $2.39 Million (-42.68% CAGR). Check latest Spago Nanomedical AB stock price today for real-time trading data and today's change.
Index Memberships
Spago Nanomedical AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.29 Billion | 0.02% | #215 of 281 |
Weight: Spago Nanomedical AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Spago Nanomedical AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Spago Nanomedical AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SPAGO net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
18.98x
Spago Nanomedical AB's market cap is 18.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $954.07 Million | $58.00K | -$7.54 Million | 16449.42x | N/A |
| 2017 | $622.96 Million | $47.00K | -$9.46 Million | 13254.54x | N/A |
| 2018 | $790.27 Million | $29.64 Million | -$11.09 Million | 26.66x | N/A |
| 2019 | $1.07 Billion | $30.00K | -$20.28 Million | 35597.90x | N/A |
| 2020 | $606.27 Million | $342.00K | -$18.90 Million | 1772.71x | N/A |
| 2021 | $341.74 Million | $660.00K | -$39.08 Million | 517.79x | N/A |
| 2022 | $44.85 Million | $1.05 Million | -$39.31 Million | 42.56x | N/A |
| 2023 | $23.28 Million | $1.20 Million | -$42.22 Million | 19.35x | N/A |
| 2024 | $13.95 Million | $1.91 Million | -$32.51 Million | 7.30x | N/A |
| 2025 | $8.29 Million | $437.00K | -$26.55 Million | 18.98x | N/A |
Competitor Companies of SPAGO by Market Capitalization
Companies near Spago Nanomedical AB in the global market cap rankings as of November 5, 2026. Also see SPAGO current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Spago Nanomedical AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Spago Nanomedical AB (2015–2026)
Market capitalization of Spago Nanomedical AB from 2015 to today. Between 2015 and today, Spago Nanomedical AB's market cap moved from $1.02 Billion to $ 2.39 Million, with a yearly change of -42.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr2.39 Million | -71.16% |
| 2025 | Skr8.29 Million | -40.56% |
| 2024 | Skr13.95 Million | -40.06% |
| 2023 | Skr23.28 Million | -48.10% |
| 2022 | Skr44.85 Million | -86.88% |
| 2021 | Skr341.74 Million | -43.63% |
| 2020 | Skr606.27 Million | -43.23% |
| 2019 | Skr1.07 Billion | +35.14% |
| 2018 | Skr790.27 Million | +26.86% |
| 2017 | Skr622.96 Million | -34.70% |
| 2016 | Skr954.07 Million | -6.45% |
| 2015 | Skr1.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Spago Nanomedical AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.39 Million USD |
| MoneyControl | $2.39 Million USD |
| MarketWatch | $2.39 Million USD |
| marketcap.company | $2.39 Million USD |
| Reuters | $2.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Spago Nanomedical AB
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well… Read more